Загрузка...
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called ho...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3916637/ https://ncbi.nlm.nih.gov/pubmed/24516334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S41786 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|